Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Product update

Ivabradine recommendations

The Pharmacological Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has made new recommendations about the use of ivabradine (Procorolan; Servier). A review of the evidence found that, out of patients with coronary artery disease, a subgroup with symptomatic angina treated with ivabridine were at higher risk of cardiovascular death or non-fatal heart attack. Following this review, PRAC has stated that the medicine should only be used for symptom relief of angina, that patients should be monitored for atrial fibrillation, and that the dose should not exceed 7.5mg twice daily and should start at 5mg twice daily, alongside other recommendations. More information can be found on the EMA website.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20067138

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.